Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
Identifieur interne : 003C68 ( Main/Merge ); précédent : 003C67; suivant : 003C69Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
Auteurs : Dan A. Mendonça [Canada] ; Krishe Menezes [Canada] ; Mandar S. Jog [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-10-31.
English descriptors
- KwdEn :
- Aged, Central Nervous System Stimulants (therapeutic use), Double-Blind Method, Fatigue (drug therapy), Fatigue (etiology), Female, Humans, Male, Methylphenidate (therapeutic use), Middle Aged, Parkinson Disease (complications), Parkinson disease, Questionnaires, Retrospective Studies, Severity of Illness Index, Statistics, Nonparametric, fatigue, methylphenidate, randomized controlled trial.
- MESH :
- chemical , therapeutic use : Central Nervous System Stimulants, Methylphenidate.
- complications : Parkinson Disease.
- drug therapy : Fatigue.
- etiology : Fatigue.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Questionnaires, Retrospective Studies, Severity of Illness Index, Statistics, Nonparametric.
Abstract
Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double‐blind, placebo‐controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty‐six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self‐report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6‐week treatment period. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21656
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001046
- to stream Istex, to step Curation: 001046
- to stream Istex, to step Checkpoint: 001854
- to stream PubMed, to step Corpus: 002569
- to stream PubMed, to step Curation: 002569
- to stream PubMed, to step Checkpoint: 002718
- to stream Ncbi, to step Merge: 001D90
- to stream Ncbi, to step Curation: 001D90
- to stream Ncbi, to step Checkpoint: 001D90
Links to Exploration step
ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21656</idno><idno type="url">https://api.istex.fr/document/C1D32DDE18D7567B439433CCEB6360B4E7088BF9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001046</idno><idno type="wicri:Area/Istex/Curation">001046</idno><idno type="wicri:Area/Istex/Checkpoint">001854</idno><idno type="wicri:doubleKey">0885-3185:2007:Mendonca D:methylphenidate:improves:fatigue</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17674415</idno><idno type="wicri:Area/PubMed/Corpus">002569</idno><idno type="wicri:Area/PubMed/Curation">002569</idno><idno type="wicri:Area/PubMed/Checkpoint">002718</idno><idno type="wicri:Area/Ncbi/Merge">001D90</idno><idno type="wicri:Area/Ncbi/Curation">001D90</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D90</idno><idno type="wicri:doubleKey">0885-3185:2007:Mendonca D:methylphenidate:improves:fatigue</idno><idno type="wicri:Area/Main/Merge">003C68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-31">2007-10-31</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2070">2070</biblScope><biblScope unit="page" to="2076">2076</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno><idno type="DOI">10.1002/mds.21656</idno><idno type="ArticleID">MDS21656</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Double-Blind Method</term><term>Fatigue (drug therapy)</term><term>Fatigue (etiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Methylphenidate (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson disease</term><term>Questionnaires</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>fatigue</term><term>methylphenidate</term><term>randomized controlled trial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fatigue</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fatigue</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Questionnaires</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double‐blind, placebo‐controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty‐six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self‐report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6‐week treatment period. © 2007 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.21656"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21656</idno><idno type="url">https://api.istex.fr/document/C1D32DDE18D7567B439433CCEB6360B4E7088BF9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001046</idno><idno type="wicri:Area/Istex/Curation">001046</idno><idno type="wicri:Area/Istex/Checkpoint">001854</idno><idno type="wicri:doubleKey">0885-3185:2007:Mendonca D:methylphenidate:improves:fatigue</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-31">2007-10-31</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2070">2070</biblScope><biblScope unit="page" to="2076">2076</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno><idno type="DOI">10.1002/mds.21656</idno><idno type="ArticleID">MDS21656</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>fatigue</term><term>methylphenidate</term><term>randomized controlled trial</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double‐blind, placebo‐controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty‐six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self‐report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6‐week treatment period. © 2007 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A" last="Mendonça">Dan A. Mendonça</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21656</idno><idno type="RBID">pubmed:17674415</idno><idno type="pmid">17674415</idno><idno type="wicri:Area/PubMed/Corpus">002569</idno><idno type="wicri:Area/PubMed/Curation">002569</idno><idno type="wicri:Area/PubMed/Checkpoint">002718</idno><idno type="wicri:Area/Ncbi/Merge">001D90</idno><idno type="wicri:Area/Ncbi/Curation">001D90</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D90</idno><idno type="wicri:doubleKey">0885-3185:2007:Mendonca D:methylphenidate:improves:fatigue</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.</title><author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A" last="Mendonça">Dan A. Mendonça</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Double-Blind Method</term><term>Fatigue (drug therapy)</term><term>Fatigue (etiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Methylphenidate (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Questionnaires</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fatigue</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fatigue</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Questionnaires</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double-blind, placebo-controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty-six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self-report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6-week treatment period.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003C68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9
|texte= Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
}}
| This area was generated with Dilib version V0.6.23. |  |